logo

Malaysia Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The Malaysia Oral Anti-Diabetic Drug Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly among younger individuals. This rising trend in diabetes cases is contributing to a growing demand for oral anti-diabetic medications. The market's expansion is influenced by the need to address diabetes-related complications, which are becoming more common due to the increasing number of affected individuals.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Malaysia Oral Anti-Diabetic Drug Market Market Size

Market Size of Malaysia Oral Anti-Diabetic Drug Industry

Malaysia Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 274 Million
Market Size (2028) USD 333 Million
CAGR (2024 - 2029) > 3.00 %

Major Players

Malaysia Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Malaysia Oral Anti-Diabetic Drug Market Analysis

The Malaysia Oral Anti-Diabetic Drug Market size is estimated at USD 274 million in 2024, and is expected to reach USD 333 million by 2028, growing at a CAGR of greater than 3% during the forecast period (2024-2028).

According to the Health Ministry, one in five Malaysians, or around 3.9 million adults and older, have diabetes. There are more young people with diabetes. The prevalence of diabetes is rising among younger people, with the number of diabetics in this age group more than doubling in the past 15 years. 

Diabetes complications, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, are becoming more prevalent due to the expanding diabetes population. Most coronavirus mortality in Malaysia is caused by underlying comorbidities, with diabetes and hypertension at the top.

Diabetes among young people is on the rise. With the number of patients between the ages of 18 and 40 having doubled over the previous 15 years, younger individuals are developing diabetes. The burden of diabetes and its consequences, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, is increasing as the number of people with diabetes grows.

Malaysia Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in Type 2 diabetes care. The Malaysia Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Need A Different Region Or Segment?
Customize Now

Malaysia Oral Anti-Diabetic Drug Market Size Summary

The Malaysia oral anti-diabetic drug market is experiencing a steady growth trajectory, driven by the increasing prevalence of diabetes among the population. The rising incidence of diabetes, particularly among younger individuals, is contributing to a growing demand for effective oral anti-diabetic medications. The market is characterized by a focus on sulfonylureas, a class of drugs used to manage type 2 diabetes, which is expected to lead the market in terms of revenue. The Malaysian government's initiatives to combat diabetes through nationwide prevention and control programs, alongside community projects supported by pharmaceutical companies, are pivotal in addressing the diabetes epidemic. These efforts aim to enhance awareness, management, and treatment of diabetes, particularly among the overweight and obese segments of the population.

The market landscape is consolidated, with major global players such as Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals dominating the scene. These companies are actively engaged in innovation to develop new diabetes treatments, reflecting a competitive environment focused on advancing therapeutic options. The approval of new drugs, such as Jardiance and Synjardy for younger patients, and Tirzepatide as a novel treatment, underscores the dynamic nature of the market. As the Malaysian population continues to grapple with high rates of diabetes and its complications, the oral anti-diabetic drug market is poised for continued expansion, supported by both governmental and corporate initiatives aimed at improving health outcomes.

Explore More

Malaysia Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

Malaysia Oral Anti-Diabetic Drug Market Size FAQs

The Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million in 2024 and grow at a CAGR of greater than 3% to reach USD 333 million by 2028.

In 2024, the Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million.

Malaysia Oral Anti-Diabetic Drug Market Report Snapshots

Malaysia Oral Anti-Diabetic Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029)